Biotech Values

[DewDiligence]

What a Moron for an analyst? “Why can’t TEVA get a new drug approved before MNTA can get the generic copax approved?”

The question pertained to Teva’s low-volume Copaxone program, which is a legitimate matter to ask about. In fact, I asked about it at MNTA’s annual meeting in June (#msg-51123550).

The dumb question on today’s webcast was not the one about low-volume Copaxone, but rather the one about whether MNTA would develop a generic version of Arixtra. That question showed no understanding whatsoever of MNTA’s expertise.